These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 32344012)

  • 1. Important considerations prior to elimination of breast cancer surgery after neoadjuvant systemic therapy: Listening to what our patients want.
    Caballero C; Piccart M
    Ann Oncol; 2020 Aug; 31(8):1083-1084. PubMed ID: 32344012
    [No Abstract]   [Full Text] [Related]  

  • 2. Optimal Selection of Breast Cancer Patients for Elimination of Surgery Following Neoadjuvant Systemic Therapy.
    Kuerer HM; Krishnamurthy S; Rauch GM; Yang WT; Smith BD; Valero V
    Ann Surg; 2018 Dec; 268(6):e61-e62. PubMed ID: 29064904
    [No Abstract]   [Full Text] [Related]  

  • 3. Patients should be the tipping point of individualizing breast cancer surgery: Commentary on 'Eliminating the breast cancer surgery paradigm after neoadjuvant systemic therapy: current evidence and future challenges'.
    Heil J; Pfob A
    Ann Oncol; 2020 Sep; 31(9):1264. PubMed ID: 32473970
    [No Abstract]   [Full Text] [Related]  

  • 4. Moving Forward with Omission of Breast Cancer Surgery Following Neoadjuvant Systemic Therapy.
    Kuerer HM
    Ann Surg Oncol; 2022 Dec; 29(13):7942-7944. PubMed ID: 36002702
    [No Abstract]   [Full Text] [Related]  

  • 5. Breast conservation following neoadjuvant therapy for breast cancer in the modern era: Are we losing the opportunity?
    Criscitiello C; Curigliano G; Burstein HJ; Wong S; Esposito A; Viale G; Giuliano M; Veronesi U; Santangelo M; Golshan M
    Eur J Surg Oncol; 2016 Dec; 42(12):1780-1786. PubMed ID: 27825710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conservative surgery after neoadjuvant chemotherapy in patients with operable breast cancer.
    Franceschini G; Di Leone A; Natale M; Sanchez MA; Masett R
    Ann Ital Chir; 2018; 89():290. PubMed ID: 30352955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evaluation of neoadjuvant therapy in breast carcinoma].
    Winzer KJ
    Chirurg; 2000 Dec; 71(12):1458-65. PubMed ID: 11195064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncologic safety of breast-conserving surgery compared to mastectomy in patients receiving neoadjuvant chemotherapy for locally advanced breast cancer.
    Cho JH; Park JM; Park HS; Park S; Kim SI; Park BW
    J Surg Oncol; 2013 Dec; 108(8):531-6. PubMed ID: 24115142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast conservation and sentinel lymph node biopsy after neoadjuvant systemic therapy.
    Veronesi P; Gentilini O; Fernandez JR; Magnoni F
    Breast; 2009 Oct; 18 Suppl 3():S90-2. PubMed ID: 19914551
    [No Abstract]   [Full Text] [Related]  

  • 10. [Neoadjuvant systemic therapy in breast cancer].
    Kahán Z; Nikolényi A; Uhercsák G; Thurzó L
    Orv Hetil; 2009 Jan; 150(2):65-71. PubMed ID: 19103557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sometimes a great notion--an assessment of neoadjuvant systemic therapy for breast cancer.
    Davidson NE; Morrow M
    J Natl Cancer Inst; 2005 Feb; 97(3):159-61. PubMed ID: 15687353
    [No Abstract]   [Full Text] [Related]  

  • 12. [Option of the surgical mode for breast cancer based on the effect of neoadjuvant chemotherapy].
    Fukutomi T
    Nihon Geka Gakkai Zasshi; 2002 Nov; 103(11):803-5. PubMed ID: 12478855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surgery following neoadjuvant chemotherapy for HER2-positive locally advanced breast cancer. Time to reconsider the standard attitude.
    Debled M; MacGrogan G; Breton-Callu C; Ferron S; Hurtevent G; Fournier M; Bourdarias L; Bonnefoi H; Mauriac L; Tunon de Lara C
    Eur J Cancer; 2015 Apr; 51(6):697-704. PubMed ID: 25704790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast conservation therapy after neoadjuvant chemotherapy: optimization of a multimodality approach.
    Caudle AS; Kuerer HM
    J Surg Oncol; 2014 Jul; 110(1):32-6. PubMed ID: 24623334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality assessment of neoadjuvant therapy use in breast conservation: barriers to implementation.
    James T; McCahill L; Ratliff J; Ashikaga T; Single R; Sheehey-Jones J; Messier N; Stanley M; Krag D; Harlow S
    Breast J; 2009; 15(5):524-6. PubMed ID: 19624412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Primary systemic chemotherapy for breast conserving surgery].
    Fukutomi T
    Nihon Rinsho; 2007 Jun; 65 Suppl 6():507-10. PubMed ID: 17682202
    [No Abstract]   [Full Text] [Related]  

  • 17. Key role for liquid biopsy in the elimination of breast cancer surgery following neoadjuvant therapy.
    Grinshpun A; Moss J; Uziely B
    Ann Oncol; 2021 Mar; 32(3):423. PubMed ID: 33301923
    [No Abstract]   [Full Text] [Related]  

  • 18. ASO Author Reflections: Nodal Downstaging and Conversion to Breast-Conserving Surgery Following Neoadjuvant Endocrine Therapy.
    Montagna G; Morrow M; Pilewskie M
    Ann Surg Oncol; 2020 Dec; 27(Suppl 3):693-694. PubMed ID: 32797378
    [No Abstract]   [Full Text] [Related]  

  • 19. [Significance and specifics of surgical treatment in locally advanced breast cancer].
    Ostapenko V; Ostapenko A
    Vopr Onkol; 2011; 57(5):578-83. PubMed ID: 22238926
    [No Abstract]   [Full Text] [Related]  

  • 20. Current and future role of neoadjuvant therapy for breast cancer.
    Untch M; Konecny GE; Paepke S; von Minckwitz G
    Breast; 2014 Oct; 23(5):526-37. PubMed ID: 25034931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.